Arthrogen’s development pipeline contains several rAAV5 vectors expressing immumodulatory cytokines or proteins that can inhibit pro-inflammatory cytokines and chemokines.

An overview is listed under product pipeline. From this proprietary portfolio of product candidates, ART-I02 has been selected for clinical development. The company is currently developing its lead product ART-I02 for the local treatment of patients with rheumatoid arthritis (see also “Lead compound”).